The Mechanism of Action of Palbociclib
Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6
Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Clinical Pearls:
- By inhibiting CDK 4 and 6, the agent prevents DNA synthesis by prohibiting progression from G1 to S phase of the cell cycle
- The agent also inhibits phosphorylation of the RB protein
- Palbociclib prohibits cell proliferation
Recent Videos
Related Content
